Harrell Investment Partners LLC Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Harrell Investment Partners LLC trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 60.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,316 shares of the medical device company’s stock after selling 8,158 shares during the period. Harrell Investment Partners LLC’s holdings in DexCom were worth $413,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of DXCM. Versant Capital Management Inc purchased a new position in DexCom during the fourth quarter valued at $25,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in DexCom during the third quarter worth about $57,000. Finally, Park Place Capital Corp grew its holdings in DexCom by 3,516.7% in the fourth quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock worth $68,000 after purchasing an additional 844 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.2 %

DexCom stock opened at $88.75 on Friday. The stock has a market cap of $34.67 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a fifty day moving average of $79.50 and a 200 day moving average of $77.35. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DXCM. Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Canaccord Genuity Group raised their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.